Small rewards lead to big wins for saving veterans' lives 

A 41% drop in death risk seen in veterans with incentives to stick with recovery from stimulants like methamphetamine and cocaine

5:00 AM

Author | Kara Gavin

person walking on green circles far away in white space
Getty Images

The chance to win a few dollars every time they pass a drug test, and the possibility of bigger prizes the longer they stay off drugs like methamphetamine and cocaine, may be enough to keep veterans from dying as they navigate early recovery, a study suggests.

In all, veterans had a 41% lower risk of dying when they received a type of care called contingency management through the Veterans Administration as part of their recovery from stimulant use disorder, compared with a closely matched group of veterans who didn’t get CM care.

Contingency management uses cash or gift certificate prizes as incentives for keeping up with substance use disorder care and days without substance use.

Past research has shown it to work across substance use disorders to promote recovery -- including for substances where there’s no medication that’s FDA-approved to aid in recovery, including stimulants.

The study suggests CM saves lives – and not just stimulant-related or drug-related deaths, but all causes of death.

It’s published in the American Journal of Psychiatry by a team from the University of Michigan and the VA Ann Arbor Healthcare System.

“This is the strongest real-world evidence to date that contingency management care for people with stimulant use disorder is linked to a significant drop in deaths. It shows the importance of the VA’s leadership in making CM available to veterans,” said Lara Coughlin, Ph.D., the addiction psychologist and health care researcher who led the study.

“We have made great progress in improving care for people with opioid use disorder, but it’s critical to also treat stimulant use disorder, with half of all overdose deaths in America now involving stimulants,” she added. “We hope these findings will help increase use of CM in the VA as well as in other settings.”

Right now, she notes, only five states have received permission to use CM in through their Medicaid programs. Michigan has a demonstration program under way that could pave the way to increase access to CM for people with substance use disorders. Private insurance coverage for CM nationwide is inconsistent.

“The VA was a decade ahead of the rest of the nation in making CM available, and that has given us the ability to study the impacts,” said Coughlin, who co-directs the Michigan Innovations in Addiction Care through Research & Education, or MI-ACRE, program with addiction psychiatrist Allison Lewei Lin, M.D., M.S., senior author of the new paper. Both Coughlin and Lin are faculty in the U-M Department of Psychiatry and members of the U-M Addiction Center, and Lin is an addiction care provider at VAAAHS.

More about the study and its findings

The researchers used data drawn from the VA’s digital health records and started with a pool of 138,280 patients diagnosed with stimulant use disorder between July 2018 and December 2020. They zeroed in on 1,481 who had received CM as part of their care, then identified 1,481 who matched those patients in multiple ways, to make a comparison group.

This is the strongest real-world evidence to date that contingency management care for people with stimulant use disorder is linked to a significant drop in deaths."

-Lara Coughlin, Ph.D. 

Their average age was 52, and 95% were male, and just over half of both groups were unhoused. Most (73%) of the veterans in both groups had gone to a VA clinic to receive care for stimulant use disorder in the last year.

Just over half also had an alcohol use disorder, 26% also had opioid use disorder, and nearly 75% had one or more major physical or mental health conditions beyond their substance use conditions.

In the year after the study period began, 27 veterans in the CM group died, compared with 46 in the comparison group.

After statistical analysis, the researchers found the 41% reduction in risk of death in the first year for those enrolled in CM. In addition, they observed a 33% reduction in risk of death by overdose, and 42% reduction in deaths that involved stimulants.

“The magnitude of these reductions are similar to what we see when people with opioid use disorder receive buprenorphine, a first line medication-based treatment for opioid use disorder, to aid their recovery,” said Coughlin.

But the study also highlights the complexity of this patient population, she says.

As a group, veterans with stimulant use disorder were twice as likely as veterans in general to die within a one-year period.

Among those with stimulant use disorder, those receiving CM were more likely to be hospitalized in the study period and were more likely to have a psychiatric hospitalization than those who didn’t receive CM. But nearly 40% of those in the non-CM group were also hospitalized.

The increase in psychiatric hospitalization in the CM group may have had a protective effect, Coughlin notes, because it may have helped veterans get intensive care for mental health conditions that might affect their ability to engage with recovery, and ultimately to stay alive.

Coughlin and colleagues note that outside the VA setting, CM has faced barriers to getting implemented, including limits on total value of incentives that a person can earn in a year, and general concern about ‘rewarding’ people with substance use conditions.

But, she said, as more CM programs begin and evidence about its real-world impact mounts, the understanding of CM as an aid to recovery is growing.

She and colleagues have also begun leading a digital form of CM, using smartphones and virtual gift card vouchers as prizes, for Michiganders with substance use disorders and for Medicaid participants in Michigan who are pregnant and use tobacco.

Additional authors: In addition to Coughlin and Lin, the study’s authors are Devin C. Tomlinson, Ph.D., Lan Zhang, Ph.D., H. Myra Kim, Sc.D., Madeline C. Frost, Ph.D., M.P.H., Gabriela Khazanov, Ph.D., James R. McKay, Ph.D., and Dominick DePhilippis, Ph.D.

Coughlin, Lin and Kim are members of the U-M Institute for Healthcare Policy and Innovation. Coughlin is Mental Health Equity Lead for the Eisenberg Family Depression Center, and Lin and Kim are also members of the VA Center for Clinical Management Research.

Funding/disclosures: The study was funded in part by the VA Office of Mental Health and Suicide Prevention.

Paper cited: “Contingency Management for Stimulant Use Disorder and Association With Mortality: A Cohort Study,” American Journal of Psychiatry. DOI: 10.1176/appi.ajp.20250053

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week.

Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows.


More Articles About:

Addiction Addiction and Mental Illness All Research Topics Wellness & Prevention Demographics Soldiers and War veterans veterans health care
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Lara N. Coughlin

Lara N Coughlin, PhD

Associate Professor

Related

Pregnant woman in pink shirt breaks a cigarette in half in front of her stomach
Health Lab

Virtual program to promote smoking cessation among Medicaid enrolled expectant mothers

Virtual program to promote smoking cessation among Medicaid enrolled expectant mothers
drawing of pills in blue ink with lab note written on bottom right in yellow and navy blue
Health Lab

Overdose deaths involving cocaine or meth tripled in shadow of opioid crisis

Study in veterans shows many fatal overdoses involved multiple substances; 70% of those who died with stimulants in their systems hadn’t received addiction treatment recently.

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

liver with yellow circles over it
Health Lab

Evolving causes, diagnosis of drug-induced liver injury

The causes of drug-induced liver injury have evolved over the last 20 years, according to a review in Hepatology Communications.
Teen girl sitting on floor next to her bed looking at a smartphone, with icons from social media apps layered over her as she frowns
Health Lab

How to improve mental health safety on social media – not just for young people

With social media companies losing or settling court cases about their products' impact on young peoples' mental health, experts offer tips for reducing impacts for those who use the platforms.
pills close up some powder some round some long
Health Lab

What’s the latest on 7-OH and kratom availability and addiction care?

The United States Drug Enforcement Agency has extended public comment on proposed temporary rescheduling of 7-OH and has rescheduled three other synthetic opioids, effectively removing them the market, leaving natural leaf kratom available amid a shortage of addiction treatment providers.
kid at table not wanting to eat breakfast with parent blurred in background white coloring milk on table
Health Lab

Many parents face challenges getting kids to eat a healthy breakfast before school

Three-quarters of parents report at least one barrier to their child starting the day with a healthy meal on a typical school day, according to the University of Michigan Health C.S. Mott Children’s Hospital National Poll on Children’s Health.
woman itching skin orange blue button down
Health Lab

A first-of-its-kind treatment for mastocytosis

A new drug called Avapritinib achieved longterm safety approval for indolent systemic mastocytosis.
Microscope images of prostate cancer cells
Health Lab

New drug combination may help treat advanced prostate cancer

University of Michigan researchers found that combining BET bromodomain and DNMT inhibitors may slow the growth of treatment-resistant prostate cancer by targeting transdifferentiated tumors.